Lenire treatment runs over about twelve weeks and involves four clinic visits and roughly an hour of home use a day. Most people considering it want to know what that actually looks like before they commit, so this is the whole process set out in order.
If you are earlier in your thinking, start with what the clinical evidence shows or whether you are a candidate.
Stage one: the hearing and tinnitus assessment
The first appointment runs around 90 minutes and it decides whether the rest of the process happens at all.
We test your hearing properly, including frequencies above the range covered in a standard screening, because tinnitus frequently sits at the edge of hearing damage that a basic test misses. We take a detailed tinnitus history: when it started, whether it is in one ear or both, what it sounds like, what makes it better or worse, and what you have already tried.
We also measure how much it is affecting you using the Tinnitus Handicap Inventory and the Tinnitus Functional Index, which are the same questionnaires used in the Lenire trials. This gives us a number rather than an impression, and it matters because the evidence for the device is concentrated in people scoring in the moderate or worse range.
You leave this appointment with a recommendation, which may or may not be Lenire. If your tinnitus is mild, or if untreated hearing loss is likely to be doing most of the work, we will say so. Lenire is a prescribed treatment rather than a product you buy, and that distinction is the point of the assessment.
Stage two: the device fitting
If you proceed, the second appointment configures the device to you.
The sound component is set against your audiogram, so the tones and background sound are matched to your hearing rather than generic. The tongue stimulation intensity is set to a level you can clearly feel without discomfort, with a range you can adjust yourself at home. The timing relationship between the sound and the pulses is set according to the stimulation protocol.
That last element is not a detail. A substantial part of the TENT-A2 trial was devoted to testing different timing settings, and different settings produced measurably different results. This is why Lenire cannot be bought over the counter and why the fitting appointment exists.
You go home with three pieces of equipment: a handheld controller that runs and times the session, Bluetooth headphones that deliver the sound, and the Tonguetip, a small intraoral device that sits on the tongue and delivers the pulses. We explain the mechanism behind all of it in bimodal neuromodulation explained.
Stage three: the first six weeks at home
Two 30-minute sessions a day. Most people do one in the morning and one in the evening, and consistency matters more than the exact timing.
During a session you sit somewhere comfortable, put on the headphones, place the Tonguetip in your mouth and start the timer. You cannot talk or eat while it runs. You can read, work at a screen, or watch something with subtitles. Most people describe the tongue sensation as a light tingling that they stop noticing within a few minutes.
Be realistic about this part. An hour a day for three months is the single most common reason people decide against Lenire, and it is better to work that out now than in week four. In TENT-A2, compliance was 83.8% at the twelve-week mark, and that was among people enrolled in a monitored clinical trial with regular contact.
Some people notice change in the first few weeks. Many do not. The trials measured their primary outcomes at twelve weeks for a reason, and an absence of change at week three tells you very little.
Stage four: the six-week review
You come back to the clinic, we repeat the questionnaires, and we compare the scores against your baseline.
This is also where the stimulation settings are usually changed. In the trials, participants were moved to a second parameter set partway through the course, and that switch was built into the protocol rather than being a response to poor progress. If your settings change at this visit, it does not mean something has gone wrong.
We also check the practical side: whether you are managing the sessions, whether the intensity is right, whether anything is uncomfortable. If your tinnitus has temporarily increased, which happens to a proportion of people, this is when we adjust.
Stage five: weeks six to twelve
The same daily routine on the revised settings. Nothing changes structurally, and this is the stretch where most of the measured benefit in the trials accumulated.
Stage six: the twelve-week review and afterwards
We repeat the questionnaires a third time. Comparing three sets of scores across twelve weeks gives you a reasonably honest picture of whether the treatment has done anything, as distinct from whether you feel like it has on the day.
From here the conversation depends on the result. Some people continue using the device at a reduced frequency as maintenance. Some stop and retain the benefit, which is what the twelve-month follow-up data in TENT-A2 describes. Some see no meaningful change, and in that case the useful thing we can do is redirect you toward the options that address the part of tinnitus a device cannot, which we cover in how Lenire compares with other tinnitus treatments.
What the trials suggest about your expectations
Three company-sponsored trials involving more than 600 people, plus two reviews of patients treated in ordinary clinics, give a reasonable basis for setting expectations.
In TENT-A2, which enrolled 191 people, the main arms recorded an average reduction of 18.5 points on the Tinnitus Handicap Inventory at twelve weeks. Of the participants still being followed twelve months after finishing, 91.0% retained a measurable improvement. In TENT-A1, the earlier and larger trial of 326 people, 80.1% of treatment-compliant participants still showed improvement at twelve months.
The most informative result is from TENT-A3, published in Nature Communications in 2024, because it was the only trial to test bimodal stimulation against sound alone. Across the full group of 112 participants, adding tongue stimulation produced no significant advantage. In the subgroup with moderate or worse tinnitus, 58.6% responded to bimodal stimulation against 43.2% for sound alone.
Read plainly: if your tinnitus is substantially bothersome, roughly six in ten people in your position get a meaningful improvement, and roughly four in ten do not. No sham-controlled trial has ever been run, so some portion of the improvement in every study reflects expectation and the natural fluctuation of tinnitus. Around a third of trial participants had a temporary increase in tinnitus at some point during treatment, generally settling before the end.
Across the trial programme, no serious adverse events related to the device were reported.
Tinnitus in Australia
Tinnitus is more common here than most people assume. A study of 4,970 employed Australians aged 18 to 64, published in the Medical Journal of Australia in 2022, found that 24.8% reported tinnitus and 5.5% experienced it constantly, which works out at roughly 529,000 working Australians living with constant tinnitus. Rates were higher in men than women.
Most of those people are managing. The treatment question arises for the smaller group whose tinnitus is interfering with sleep, concentration or mood, and that group is where the Lenire evidence sits.
Who Lenire is not for
Lenire is for adults aged 18 and over with chronic subjective tinnitus. It is not suitable if you have a pacemaker, defibrillator or other active implantable device, if you are pregnant, if you have epilepsy or another condition that can cause loss of consciousness, if you have impaired sensation in the tongue, if you have oral inflammation, sores or lesions, if you have intermittent or chronic neuralgia in the head or neck, or if you have oral piercings. Some of these can be reconsidered on the direction of your doctor or dentist.
Objective tinnitus, where the sound has a physical source, is a contraindication. The device has not been evaluated for Meniere’s disease. The eligibility article covers this in full.
Frequently asked questions
How long does Lenire treatment take?
Two 30-minute sessions daily over approximately twelve weeks, with clinic appointments at the start, at around six weeks, and at twelve weeks. The manufacturer’s minimum recommendation is ten weeks. The clinical trials measured outcomes at twelve.
Can I buy Lenire over the counter?
No. Lenire is configured to your individual hearing and tinnitus profile and is supplied only through trained provider clinics following a consultation.
How many appointments do I need?
Four in a standard course: the initial assessment, the device fitting, a review at around six weeks, and a review at twelve weeks. For patients travelling a long distance, some reviews can often be handled remotely.
When will I notice a difference?
There is no reliable answer. Some people report change within the first few weeks, others late in the course, and some not at all. The trials assessed their main outcomes at twelve weeks, and an absence of change early on is not informative.
What happens after the twelve weeks?
Depending on your result, you may continue at a reduced frequency, stop and retain the benefit, or move to a different approach. In TENT-A2, most participants who responded still showed improvement twelve months after finishing.
Book a Lenire assessment
The Audiology Place is one of two Lenire provider clinics in New South Wales. We assess at Forestville and Epping. Call (02) 9315 8327 or book online.
References
- Conlon B, Langguth B, Hamilton C, et al. Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study. Science Translational Medicine. 2020;12(564). doi:10.1126/scitranslmed.abb2830
- Conlon B, Hamilton C, Meade E, et al. Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial. Scientific Reports. 2022;12:10845. doi:10.1038/s41598-022-13875-x
- Boedts M, Buechner A, Guerit F, et al. Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial. Nature Communications. 2024;15. doi:10.1038/s41467-024-50473-z
- Lewkowski K, Heyworth JS, Ytterstad E, Williams W, Goulios H, Fritschi L. The prevalence of tinnitus in the Australian working population. Medical Journal of Australia. 2022;216(4). mja.com.au
- Neuromod Devices. What patients are unsuitable for Lenire?
- Neuromod Devices. Lenire patient information brochure, MM0003 V7.0.
- Therapeutic Goods Administration. ARTG entry 511728, Lenire.
Reviewed by Dr Signe Steers, Audiologist, The Audiology Place. Last updated September 2026. The Audiology Place supplies Lenire commercially. This article provides general information and is not a substitute for individual clinical assessment.
